Point-of-Care Coagulation Testing Market Size, Share and Growth Outlook 2026: By Product Type (Devices/Analyzers, Consumables), By Test Type, By Technology, By Sample Type, By End User, Companies to 2034.
The global Point-of-Care Coagulation Testing Market size is forecast to increase from $3.1 Billion in 2026 to $5.49 Billion in 2034 at a CAGR of 7.4% between 2026 and 2034.
The Point-of-Care Coagulation Testing market report provides detailed analysis and outlook of Point-of-Care Coagulation Testing segments including By Product Type (Devices/Analyzers, Consumables), By Test Type (Prothrombin Time, Activated Clotting Time, Activated Partial Thromboplastin Time, Viscoelastic Tests, D-dimer and Fibrin Degradation Tests), By Technology (Electrochemical Detection, Optical Detection, Mechanical/Viscoelastic Sensing, Ultrasound-based Resonance), By Sample Type (Whole Blood, Capillary Blood, Plasma), By End User (Hospitals and Clinics, Diagnostic Laboratories, Blood Banks and Transfusion Centers, Home-care Settings, Others) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Point-of-Care Coagulation Testing Industry Overview
Decentralized Hemostasis Testing and Digital Connectivity are Reshaping Point-of-Care Coagulation Diagnostics
The Point-of-Care Coagulation Testing industry is experiencing rapid advancement as hospitals, critical care units, and surgical centers increasingly adopt decentralized diagnostic platforms capable of delivering immediate hemostatic information at the bedside. Rising demand for rapid bleeding assessment, anticoagulation monitoring, perioperative management, and critical care decision support has accelerated the transition from centralized laboratory testing toward integrated point-of-care coagulation ecosystems. Healthcare providers are prioritizing technologies that improve clinical response times, reduce laboratory burden, and enable real-time therapeutic interventions. Advances in cartridge-based diagnostics, automated quality management systems, digital connectivity, and integrated hospital analytics are driving substantial innovation across the coagulation testing landscape.
Integrated Point-of-Care Platforms are Enhancing Critical Care and Surgical Decision-Making
The growing complexity of cardiovascular procedures, trauma management, and critical care medicine has increased demand for point-of-care systems capable of simultaneously evaluating multiple physiological parameters. Manufacturers are increasingly developing integrated platforms that combine coagulation assessment with broader patient monitoring capabilities to support rapid clinical interventions. Werfen has strengthened this market trend through the expanded commercialization of its GEM® Premier™ 7000 with iQM®3 platform across European healthcare systems. The cartridge-based system integrates blood gas analysis with whole-blood hemostasis monitoring while utilizing automated quality management technologies to support immediate clinical decisions involving transfusion management, bleeding risk assessment, and anticoagulation dosing. These capabilities reflect the broader industry movement toward comprehensive near-patient diagnostic platforms that improve workflow efficiency and patient outcomes in high-acuity environments.
Networked Diagnostics and Digital Health Integration are Transforming Coagulation Testing Workflows
The point-of-care coagulation testing market is increasingly evolving toward highly connected diagnostic ecosystems that integrate decentralized testing with centralized laboratory management and hospital-wide clinical information systems. Werfen has further advanced this trend through commercialization of its ACL TOP® Family 70 Series Hemostasis Testing Systems, which enable remote coagulation testing data to be incorporated into centralized laboratory workflows while optimizing analytical performance and reducing operational burden. Simultaneously, major diagnostic companies are investing heavily in digital integration strategies to strengthen connectivity across healthcare networks. Roche has identified point-of-care diagnostics and digital health infrastructure as strategic priorities, with ongoing investments focused on linking decentralized coagulation testing devices directly into hospital-wide analytical management systems. These developments highlight the broader transition of the point-of-care coagulation testing industry toward intelligent, interconnected, and data-driven diagnostic environments designed to accelerate clinical decision-making and improve management of critical bleeding events.
Point-of-Care Coagulation Testing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Point-of-Care Coagulation Testing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation (Beckman Coulter / Radiometer), Werfen (Instrumentation Laboratory), Sysmex Corporation, bioM?rieux SA, Universal Biosensors, HemoSonics, LLC (Stago Group), i-SENS, Inc. (CoaguSense). The Point-of-Care Coagulation Testing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Point-of-Care Coagulation Testing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Point-of-Care Coagulation Testing industry include- F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation (Beckman Coulter / Radiometer), Werfen (Instrumentation Laboratory), Sysmex Corporation, bioM?rieux SA, Universal Biosensors, HemoSonics, LLC (Stago Group), i-SENS, Inc. (CoaguSense). The Point-of-Care Coagulation Testing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Point-of-Care Coagulation Testing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Point-of-Care Coagulation Testing market remains one of the strongest-performing segments in the country.
The US Point-of-Care Coagulation Testing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Point-of-Care Coagulation Testing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Point-of-Care Coagulation Testing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Point-of-Care Coagulation Testing markets
Canada's strong Point-of-Care Coagulation Testing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Point-of-Care Coagulation Testing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Point-of-Care Coagulation Testing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Point-of-Care Coagulation Testing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Point-of-Care Coagulation Testing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Point-of-Care Coagulation Testing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Point-of-Care Coagulation Testing market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Point-of-Care Coagulation Testing sales through 2034
France Point-of-Care Coagulation Testing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Point-of-Care Coagulation Testing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Point-of-Care Coagulation Testing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Point-of-Care Coagulation Testing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Point-of-Care Coagulation Testing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Point-of-Care Coagulation Testing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Point-of-Care Coagulation Testing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Point-of-Care Coagulation Testing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Point-of-Care Coagulation Testing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Point-of-Care Coagulation Testing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Point-of-Care Coagulation Testing Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Point-of-Care Coagulation Testing Market Segmentation
By Product Type
Devices/Analyzers
Consumables
By Test Type
Prothrombin Time
Activated Clotting Time
Activated Partial Thromboplastin Time
Viscoelastic Tests
D-dimer and Fibrin Degradation Tests
By Technology
Electrochemical Detection
Optical Detection
Mechanical/Viscoelastic Sensing
Ultrasound-based Resonance
By Sample Type
Whole Blood
Capillary Blood
Plasma
By End User
Hospitals and Clinics
Diagnostic Laboratories
Blood Banks and Transfusion Centers
Home-care Settings
Others
Leading Companies in Point-of-Care Coagulation Testing Industry (2026)
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation (Beckman Coulter / Radiometer)
Werfen (Instrumentation Laboratory)
Sysmex Corporation
bioM?rieux SA
Universal Biosensors
HemoSonics, LLC (Stago Group)
i-SENS, Inc. (CoaguSense)
Countries Included
The Point-of-Care Coagulation Testing market report provides detailed analysis and outlook of Point-of-Care Coagulation Testing segments including By Product Type (Devices/Analyzers, Consumables), By Test Type (Prothrombin Time, Activated Clotting Time, Activated Partial Thromboplastin Time, Viscoelastic Tests, D-dimer and Fibrin Degradation Tests), By Technology (Electrochemical Detection, Optical Detection, Mechanical/Viscoelastic Sensing, Ultrasound-based Resonance), By Sample Type (Whole Blood, Capillary Blood, Plasma), By End User (Hospitals and Clinics, Diagnostic Laboratories, Blood Banks and Transfusion Centers, Home-care Settings, Others) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Point-of-Care Coagulation Testing Industry Overview
Decentralized Hemostasis Testing and Digital Connectivity are Reshaping Point-of-Care Coagulation Diagnostics
The Point-of-Care Coagulation Testing industry is experiencing rapid advancement as hospitals, critical care units, and surgical centers increasingly adopt decentralized diagnostic platforms capable of delivering immediate hemostatic information at the bedside. Rising demand for rapid bleeding assessment, anticoagulation monitoring, perioperative management, and critical care decision support has accelerated the transition from centralized laboratory testing toward integrated point-of-care coagulation ecosystems. Healthcare providers are prioritizing technologies that improve clinical response times, reduce laboratory burden, and enable real-time therapeutic interventions. Advances in cartridge-based diagnostics, automated quality management systems, digital connectivity, and integrated hospital analytics are driving substantial innovation across the coagulation testing landscape.
Integrated Point-of-Care Platforms are Enhancing Critical Care and Surgical Decision-Making
The growing complexity of cardiovascular procedures, trauma management, and critical care medicine has increased demand for point-of-care systems capable of simultaneously evaluating multiple physiological parameters. Manufacturers are increasingly developing integrated platforms that combine coagulation assessment with broader patient monitoring capabilities to support rapid clinical interventions. Werfen has strengthened this market trend through the expanded commercialization of its GEM® Premier™ 7000 with iQM®3 platform across European healthcare systems. The cartridge-based system integrates blood gas analysis with whole-blood hemostasis monitoring while utilizing automated quality management technologies to support immediate clinical decisions involving transfusion management, bleeding risk assessment, and anticoagulation dosing. These capabilities reflect the broader industry movement toward comprehensive near-patient diagnostic platforms that improve workflow efficiency and patient outcomes in high-acuity environments.
Networked Diagnostics and Digital Health Integration are Transforming Coagulation Testing Workflows
The point-of-care coagulation testing market is increasingly evolving toward highly connected diagnostic ecosystems that integrate decentralized testing with centralized laboratory management and hospital-wide clinical information systems. Werfen has further advanced this trend through commercialization of its ACL TOP® Family 70 Series Hemostasis Testing Systems, which enable remote coagulation testing data to be incorporated into centralized laboratory workflows while optimizing analytical performance and reducing operational burden. Simultaneously, major diagnostic companies are investing heavily in digital integration strategies to strengthen connectivity across healthcare networks. Roche has identified point-of-care diagnostics and digital health infrastructure as strategic priorities, with ongoing investments focused on linking decentralized coagulation testing devices directly into hospital-wide analytical management systems. These developments highlight the broader transition of the point-of-care coagulation testing industry toward intelligent, interconnected, and data-driven diagnostic environments designed to accelerate clinical decision-making and improve management of critical bleeding events.
Point-of-Care Coagulation Testing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Point-of-Care Coagulation Testing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation (Beckman Coulter / Radiometer), Werfen (Instrumentation Laboratory), Sysmex Corporation, bioM?rieux SA, Universal Biosensors, HemoSonics, LLC (Stago Group), i-SENS, Inc. (CoaguSense). The Point-of-Care Coagulation Testing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Point-of-Care Coagulation Testing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Point-of-Care Coagulation Testing Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Point-of-Care Coagulation Testing companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Point-of-Care Coagulation Testing markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Point-of-Care Coagulation Testing industry include- F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation (Beckman Coulter / Radiometer), Werfen (Instrumentation Laboratory), Sysmex Corporation, bioM?rieux SA, Universal Biosensors, HemoSonics, LLC (Stago Group), i-SENS, Inc. (CoaguSense). The Point-of-Care Coagulation Testing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Point-of-Care Coagulation Testing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Point-of-Care Coagulation Testing market remains one of the strongest-performing segments in the country.
The US Point-of-Care Coagulation Testing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Point-of-Care Coagulation Testing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Point-of-Care Coagulation Testing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Point-of-Care Coagulation Testing markets
Canada's strong Point-of-Care Coagulation Testing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Point-of-Care Coagulation Testing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Point-of-Care Coagulation Testing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Point-of-Care Coagulation Testing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Point-of-Care Coagulation Testing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Point-of-Care Coagulation Testing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Point-of-Care Coagulation Testing market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Point-of-Care Coagulation Testing sales through 2034
France Point-of-Care Coagulation Testing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Point-of-Care Coagulation Testing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Point-of-Care Coagulation Testing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Point-of-Care Coagulation Testing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Point-of-Care Coagulation Testing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Point-of-Care Coagulation Testing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Point-of-Care Coagulation Testing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Point-of-Care Coagulation Testing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Point-of-Care Coagulation Testing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Point-of-Care Coagulation Testing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Point-of-Care Coagulation Testing Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Point-of-Care Coagulation Testing Market Segmentation
By Product Type
Devices/Analyzers
Consumables
By Test Type
Prothrombin Time
Activated Clotting Time
Activated Partial Thromboplastin Time
Viscoelastic Tests
D-dimer and Fibrin Degradation Tests
By Technology
Electrochemical Detection
Optical Detection
Mechanical/Viscoelastic Sensing
Ultrasound-based Resonance
By Sample Type
Whole Blood
Capillary Blood
Plasma
By End User
Hospitals and Clinics
Diagnostic Laboratories
Blood Banks and Transfusion Centers
Home-care Settings
Others
Leading Companies in Point-of-Care Coagulation Testing Industry (2026)
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation (Beckman Coulter / Radiometer)
Werfen (Instrumentation Laboratory)
Sysmex Corporation
bioM?rieux SA
Universal Biosensors
HemoSonics, LLC (Stago Group)
i-SENS, Inc. (CoaguSense)
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Point-of-Care Coagulation Testing Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Point-of-Care Coagulation Testing Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL POINT-OF-CARE COAGULATION TESTING MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Point-of-Care Coagulation Testing Markets in 2026
3.2. Global Historic and Forecast Point-of-Care Coagulation Testing Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Point-of-Care Coagulation Testing Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Point-of-Care Coagulation Testing Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Point-of-Care Coagulation Testing Value Chain
CHAPTER 4- POINT-OF-CARE COAGULATION TESTING MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Point-of-Care Coagulation Testing Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- POINT-OF-CARE COAGULATION TESTING MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Type
Devices/Analyzers
Consumables
By Test Type
Prothrombin Time
Activated Clotting Time
Activated Partial Thromboplastin Time
Viscoelastic Tests
D-dimer and Fibrin Degradation Tests
By Technology
Electrochemical Detection
Optical Detection
Mechanical/Viscoelastic Sensing
Ultrasound-based Resonance
By Sample Type
Whole Blood
Capillary Blood
Plasma
By End User
Hospitals and Clinics
Diagnostic Laboratories
Blood Banks and Transfusion Centers
Home-care Settings
Others
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Point-of-Care Coagulation Testing Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
7.5. North America Point-of-Care Coagulation Testing Market Size Outlook by Type
7.6. North America Point-of-Care Coagulation Testing Market Size Outlook by Application
7.7. North America Point-of-Care Coagulation Testing Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Point-of-Care Coagulation Testing Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Point-of-Care Coagulation Testing Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Point-of-Care Coagulation Testing Companies
CHAPTER 8- EUROPE POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Point-of-Care Coagulation Testing Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
8.5. Europe Point-of-Care Coagulation Testing Market Size Outlook by Type
8.6. Europe Point-of-Care Coagulation Testing Market Size Outlook by Application
8.7. Europe Point-of-Care Coagulation Testing Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Point-of-Care Coagulation Testing Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Point-of-Care Coagulation Testing Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Point-of-Care Coagulation Testing Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Point-of-Care Coagulation Testing Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Point-of-Care Coagulation Testing Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Point-of-Care Coagulation Testing Companies
CHAPTER 9- ASIA PACIFIC POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Point-of-Care Coagulation Testing Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Point-of-Care Coagulation Testing Market Size Outlook by Type
9.6. Asia Pacific Point-of-Care Coagulation Testing Market Size Outlook by Application
9.7. Asia Pacific Point-of-Care Coagulation Testing Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Point-of-Care Coagulation Testing Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Point-of-Care Coagulation Testing Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Point-of-Care Coagulation Testing Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Point-of-Care Coagulation Testing Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Point-of-Care Coagulation Testing Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Point-of-Care Coagulation Testing Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Point-of-Care Coagulation Testing Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
10.5. South and Central America Point-of-Care Coagulation Testing Market Size Outlook by Type
10.6. South and Central America Point-of-Care Coagulation Testing Market Size Outlook by Application
10.7. South and Central America Point-of-Care Coagulation Testing Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Point-of-Care Coagulation Testing Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Point-of-Care Coagulation Testing Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Point-of-Care Coagulation Testing Companies
CHAPTER 11- MIDDLE EAST AND AFRICA POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Point-of-Care Coagulation Testing Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Point-of-Care Coagulation Testing Market Size Outlook by Type
11.6. Middle East and Africa Point-of-Care Coagulation Testing Market Size Outlook by Application
11.7. Middle East and Africa Point-of-Care Coagulation Testing Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Point-of-Care Coagulation Testing Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Point-of-Care Coagulation Testing Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Point-of-Care Coagulation Testing Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Point-of-Care Coagulation Testing Industry
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation (Beckman Coulter / Radiometer)
Werfen (Instrumentation Laboratory)
Sysmex Corporation
bioM?rieux SA
Universal Biosensors
HemoSonics, LLC (Stago Group)
i-SENS, Inc. (CoaguSense)
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Point-of-Care Coagulation Testing Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Point-of-Care Coagulation Testing Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL POINT-OF-CARE COAGULATION TESTING MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Point-of-Care Coagulation Testing Markets in 2026
3.2. Global Historic and Forecast Point-of-Care Coagulation Testing Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Point-of-Care Coagulation Testing Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Point-of-Care Coagulation Testing Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Point-of-Care Coagulation Testing Value Chain
CHAPTER 4- POINT-OF-CARE COAGULATION TESTING MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Point-of-Care Coagulation Testing Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- POINT-OF-CARE COAGULATION TESTING MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Type
Devices/Analyzers
Consumables
By Test Type
Prothrombin Time
Activated Clotting Time
Activated Partial Thromboplastin Time
Viscoelastic Tests
D-dimer and Fibrin Degradation Tests
By Technology
Electrochemical Detection
Optical Detection
Mechanical/Viscoelastic Sensing
Ultrasound-based Resonance
By Sample Type
Whole Blood
Capillary Blood
Plasma
By End User
Hospitals and Clinics
Diagnostic Laboratories
Blood Banks and Transfusion Centers
Home-care Settings
Others
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Point-of-Care Coagulation Testing Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
7.5. North America Point-of-Care Coagulation Testing Market Size Outlook by Type
7.6. North America Point-of-Care Coagulation Testing Market Size Outlook by Application
7.7. North America Point-of-Care Coagulation Testing Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Point-of-Care Coagulation Testing Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Point-of-Care Coagulation Testing Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Point-of-Care Coagulation Testing Companies
CHAPTER 8- EUROPE POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Point-of-Care Coagulation Testing Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
8.5. Europe Point-of-Care Coagulation Testing Market Size Outlook by Type
8.6. Europe Point-of-Care Coagulation Testing Market Size Outlook by Application
8.7. Europe Point-of-Care Coagulation Testing Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Point-of-Care Coagulation Testing Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Point-of-Care Coagulation Testing Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Point-of-Care Coagulation Testing Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Point-of-Care Coagulation Testing Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Point-of-Care Coagulation Testing Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Point-of-Care Coagulation Testing Companies
CHAPTER 9- ASIA PACIFIC POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Point-of-Care Coagulation Testing Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Point-of-Care Coagulation Testing Market Size Outlook by Type
9.6. Asia Pacific Point-of-Care Coagulation Testing Market Size Outlook by Application
9.7. Asia Pacific Point-of-Care Coagulation Testing Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Point-of-Care Coagulation Testing Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Point-of-Care Coagulation Testing Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Point-of-Care Coagulation Testing Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Point-of-Care Coagulation Testing Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Point-of-Care Coagulation Testing Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Point-of-Care Coagulation Testing Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Point-of-Care Coagulation Testing Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
10.5. South and Central America Point-of-Care Coagulation Testing Market Size Outlook by Type
10.6. South and Central America Point-of-Care Coagulation Testing Market Size Outlook by Application
10.7. South and Central America Point-of-Care Coagulation Testing Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Point-of-Care Coagulation Testing Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Point-of-Care Coagulation Testing Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Point-of-Care Coagulation Testing Companies
CHAPTER 11- MIDDLE EAST AND AFRICA POINT-OF-CARE COAGULATION TESTING MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Point-of-Care Coagulation Testing Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Point-of-Care Coagulation Testing Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Point-of-Care Coagulation Testing Market Size Outlook by Type
11.6. Middle East and Africa Point-of-Care Coagulation Testing Market Size Outlook by Application
11.7. Middle East and Africa Point-of-Care Coagulation Testing Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Point-of-Care Coagulation Testing Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Point-of-Care Coagulation Testing Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Point-of-Care Coagulation Testing Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Point-of-Care Coagulation Testing Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Point-of-Care Coagulation Testing Industry
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation (Beckman Coulter / Radiometer)
Werfen (Instrumentation Laboratory)
Sysmex Corporation
bioM?rieux SA
Universal Biosensors
HemoSonics, LLC (Stago Group)
i-SENS, Inc. (CoaguSense)
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
